In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
The oral MET inhibitor, marketed as Tabrecta, is for patients whose tumors have a mutation that leads to MET exon 14 skipping as detected by a Foundation Medicine test.
